Cetuximab for Head and Neck Cancer
Cetuximab (Erbitux) is now approved for use in combination with radiation therapy to treat patients with un-resectable squamous cell cancer of the head and neck. It is manufactured by ImClone Systems and will be distributed and marketed by Bristol-Myers Squibb. prevacid drug This is the first drug approved for head and neck cancer that has shown [...]
Read User's Comments





